

Alternative Splicing of Murine Interleukin-4 mRNA

O. P. Yatsenko, M. L. Filipenko*, E. N. Voronina*,
E. A. Khrapov*, S. V. Sennikov, and V. A. Kozlov

Translated from *Byulleten' Eksperimental'noi Biologii i Meditsiny*, Vol. 137, No. 2, pp. 202-205, February, 2004
Original article submitted September 16, 2003

We found an alternative form of mRNA with spliced second exon (IL-4 δ 2 mRNA) in mouse bone marrow and splenic cells. At rest, the amount of IL-4 mRNA markedly surpassed that of IL-4 δ 2 mRNA. Stimulation increased the content of both mRNA forms, but the alternative variant is accumulated more intensively and rapidly. We did not detect predominance of IL-4 δ 2 mRNA over full-length mRNA variant in the studied mouse tissues.

Key Words: interleukin-4; alternative splicing

Interleukin-4 (IL-4) is a key type T_H2 cytokines. In humans *IL-4* gene is expressed in two mRNA forms: full-length form containing all 4 exons and alternatively spliced mRNA form without exon 2: IL-4 δ 2 [3,9,13]. IL-4 δ 2 mRNA was detected in higher primates and rabbits [8,11], as well as one more mRNA isoform IL-4 δ 3 with exon 3 deletion. Recombinant human protein IL-4 δ 2 (rhIL-4 δ 2) can bind to IL-4 receptor and inhibit the effect of recombinant human IL-4 (rhIL-4) on immunocompetent cells [4,5]. On the other hand, rhIL-4 δ 2 acts as IL-4 agonist in human lung and skin fibroblasts and stimulates α 2 collagen(I) mRNA transcription [6]. Hence, we can speak about tissue-specific effects of IL-4 isoforms.

Tissue-specific distribution of IL-4 mRNA isoforms was discovered. Normally IL-4 δ 2 mRNA is present in human peripheral blood mononuclear cells (MNC) in minor amounts [3], though in some donors it can be dominant in comparison with the full-length form [3,5]. IL-4 δ 2 mRNA predominated over the full-length form in the thymus and bronchoalveolar lavage cells [5], in M95/8 and HJ60 cells [10]. The ratio of two IL-4 mRNA forms is changed in some diseases [9,12-14], which is believed to be an important factor in the pathogenesis of these diseases. Based on the

data on tissue-specific distribution and activity of IL-4 isoforms and suggesting that the regulation of this gene splicing is similar in different species of mammals, we hypothesized the presence of an alternative IL-4 variant in mice — a convenient object for studies of this variant expression.

We studied IL-4 mRNA isoforms in mice, evaluated their levels, and investigated their tissue-specific expression in ontogeny.

MATERIALS AND METHODS

Intact (DBA/2J \times C57BL/6J)F1 animals were used in the study: embryos, newborns, and male mice aged 3-6 months, bred in Tomsk Research Center and Laboratory of Experimental Animals (Models) of Institute of Clinical Immunology. Organs from animals were homogenized with a syringe, resuspended in RPMI-1640, cells were counted and their viability was evaluated. Bone marrow MNC were isolated in Ficoll-urograffin 1.082 density gradient (Sigma). The isolated cells were cultured or placed into a lysing solution (1×10^6 cells) [7] and stored at -20°C until use. Liver, thymus, lung, lymph node, Peyer's patches, intestinal wall, muscle tissues, placenta, and embryonal tissues (embryonal liver on days 11 and 15 and brain after 14-day gestation) were taken on cold for investigation of tissue-specific expression. Tissue collected from each mouse was frozen in liquid nitrogen and stored at -70°C.

Laboratory of Immunopoesis Regulation, Institute of Clinical Immunology, Siberian Division of Russian Academy of Medical Sciences; *Institute of Chemical Biology and Fundamental Medicine, Siberian Division of Russian Academy of Sciences, Novosibirsk. **Address for correspondence:** ici@online.nsc.su. Sennikov S. V.

The cells (5×10^6) were cultured *in vitro* in Petri dishes in RPMI-1640 with 2 mM L-glutamine, 5% inactivated fetal calf serum, 50 μ M β_2 -mercaptoethanol, and gentamicin (80 μ g/ml) for 48 h in a CO₂ incubator at 37°C. Mitogens were added into culture medium once at the start of culturing: concanavalin A (con A, Sigma) in a dose of 10 μ g/1 million cells and *E. coli* 055:B5 LPS (Sigma) — 30 μ g/1 million cells.

RNA was isolated from mouse tissues as described previously [7]. The quality of summary RNA was evaluated by electrophoresis in 1.5% agarose gel, its quantity was measured by spectrophotometry at 260 nm. RNA was stored at -70°C. cDNA was isolated from 1 μ g summary RNA in reverse transcription (RT) reaction with 5 μ M d(pT)₁₈ primer and MoMLV RNA-dependent DNA polymerase (100 U, Institute of Chemical Biology and Fundamental Medicine) in 20 μ l buffer containing 20 mM Tris-HCl (pH 8.3), 2 mM MnCl₂, 5 mM dithiothreitol, 100 mM KCl, and 400 μ M dNTP.

PCR was carried out in 20 μ l reaction mixture with 1 U Taq polymerase (Institute of Chemical Biology and Fundamental Medicine). Amplification mixture contained 2 μ l (approximately 50 ng) cDNA for matrix, 200 μ M dNTP solution in standard buffer: 67 mM Tris-HCl (pH 8.9), 16 mM ammonium sulfate, 1.5 mM MgCl₂, 0.05% Tween-20, and 20 pM each primer for amplification. PCR conditions were as follows: 3 min denaturing at 95°C, 40 cycles of 7 sec at 95°C, 7 sec at 62°C, and 12 sec at 72°C, followed by the final elongation cycle (3 min at 72°C).

Deoxyribooligonucleotide primers were synthesized at the Institute of Chemical Biology and Fundamental Medicine and had the following nucleotide sequences: IL-4m-d CAGGAGAAGGGAACACCAC, IL-4m-n TGGATGTGCCAAACGTCC, IL-4m-r G(G,C)TCTTTAG(G,C)CTTTCCA(A,G)GAAG.

Competitive PCR was carried out as described previously [2]. Competitive standard DNA for measuring IL-4 and IL-4 δ 2 cDNA were obtained by amplification of phage T7 genome DNA with primers specific for the studied cDNA using low annealing temperature for the first cycles.

Amplification products (10 μ l) were separated by electrophoresis in 6% PAAG or 1.5% agarose gel. The gel was stained with ethidium bromide (0.5 mg/ml) and DNA was visualized in UV light. The image was

fixed using Watec AD-901 CD camera (Watec Co. Ltd.).

DNA content was calculated by band density using ScionImage software. A curve was plotted, presenting the linear relationship between the logarithm of the ratio of the level of competitive DNA to the studied cDNA to the logarithm of the initial concentrations of competitive DNA, in which it was added to the PCR mixture. The equivalence point was determined (zero ratio of the logarithm of competitive DNA to cDNA) and the initial level of the studied cDNA corresponded to the initial level of competitive DNA. The mean value and the standard error in the mean were calculated for each cDNA by the results of 3 repeated measurements.

Amplification products were eluted from the gel as described previously [1]. Sequencing was carried out using BigDye kit (Amersham) according to the manufacturer's recommendations. Electrophoretic separation of sequencing products was carried out on an automated ABI310 DNA sequencer. The resultant nucleotide sequences were analyzed using Vector NTI software (Informatics).

RESULTS

Deoxyribooligonucleotide primers were constructed for selective detection of full-length IL-4 and IL-4 δ 2 mRNA. The primer for full-length IL-4 variant contained a sequence complementary to the region of the end of exon 1 and beginning of exon 2, that for IL-4 δ 2 included a sequence of the end of exon 1 and beginning of exon 3. The reverse primer, common for both forms, was situated in exon 4 region (Fig. 1).

In order to detect mouse IL-4 δ 2 mRNA, summary cDNA were obtained from mouse splenocytes and MNC and cultured *in vitro* with Con A, LPS, and without mitogens. Electrophoretic separation of amplification products of the above cDNA with primers IL-4m-d/IL4m-r showed a fragment of expected size (254 n. p.) in Con A-stimulated splenic and bone marrow cells (Fig. 2). The nucleotide structure of this DNA fragment was determined by direct Sanger sequencing; it corresponded to mouse IL4 δ 2 mRNA and was called mIL-4 δ 2. This product was not detected in cDNA samples from cell cultures without mitogens or those stimulated with LPS. On the other hand, PCR




Fig. 1. Scheme of oligonucleotide primers.




Fig. 2. Electrophoregram of amplification products with IL4m-d and IL4m-r for mouse splenocyte cDNA. C: without mitogen stimulation; Con A: stimulation with concanavalin A; M: BluscriptIIKS/HaeIII. Arrow: 254 n. p. DNA fragment corresponding to IL-4 δ 2 cDNA.

products identical to IL-4 mRNA (264 n. p.) were present in all samples. We hypothesized that the alternative form is also expressed in cell resting, but in quantities below the sensitivity of RT-PCR method. Later the presence of minor amounts of IL-4 δ 2 mRNA in intact bone marrow and splenic cells was confirmed by inserted PCR, which was more sensitive (data not presented).

The study of the kinetics of IL-4mRNA and IL-4 δ 2mRNA expression in mouse splenocyte culture showed that Con A stimulation resulted in induction of both IL-4 and IL-4 δ 2 mRNA. The maximum level of IL-4 δ 2 mRNA was observed 3 h after addition of Con A, but then it decreased. Minor amounts of IL-4 δ 2 mRNA were detected in cells until 48 h in culture. The peak of IL-4 mRNA induction was observed 6 h after the start of stimulation, after which mRNA level gradually decreased (Fig. 3). Competitive quantitative PCR showed that the content of full-length mRNA at the peak of induction (6 h) 14 times surpassed the level of IL-4 δ 2 mRNA.




Fig. 3. Kinetics of IL-4 mRNA (1) and IL-4 δ 2 (2) expression in mouse splenocyte cultures.

In order to study the tissue-specific distribution of mouse IL-4 mRNA isoforms, we isolated RNA and synthesized cDNA from the liver, thymus, lung, lymph nodes, Peyer's patches, intestinal wall, muscle tissues, placenta, and embryonal tissues (on days 11 and 15 of gestation from the liver and on 14 day from the brain). We found no IL-4 δ 2 mRNA in native tissues by single-stage PCR, while inserted PCR detected IL-4 δ 2 in minor quantities in all the studied samples (data not presented).

Our findings indicate that in mammals (starting from mice) IL-4 gene is expressed in 2 forms of mRNA (full-length and alternatively spliced by exon 2). In contrast to humans, alternative mRNA form (IL-4 δ 2) in mice is not tissue-specific and is expressed in lymphoid and hemopoietic tissue as a minor form in comparison with full-length variant. The same is true for the expression of two IL-4 mRNA forms in ontogeny.

It is noteworthy that stimulation of mouse splenocytes by Con A mitogen led to an increase in the content of IL-4 and IL-4 δ 2 mRNA, similarly as in human peripheral blood MNC [10], but even in this case the level of IL-4 δ 2 mRNA was considerably lower than that of the full-length IL-4 mRNA.

The study was supported by the Russian Foundation for Basic Research (grant No. 03-04-49397).

REFERENCES

1. T. Maniatis, E. Fritsch, and J. Sambrook, *Molecular Cloning* [in Russian], Moscow (1984).
2. O. A. Timofeeva, M. L. Filipenko, and N. A. Rychkova, *Bio-khimiya*, **65**, No. 6, 106-111 (2000).
3. W. J. Alms, S. P. Atamas, and V. V. Yurovsky, *Mol. Immunol.*, **33**, No. 4/5, 361-370 (1996).
4. Y. Arinobu, S. P. Atamas, T. Otsuka, et al., *Cell Immunol.*, **191**, 161-167 (1999).
5. S. P. Atamas, J. Choi, V. V. Yurovsky, et al., *J. Immunol.*, **156**, No. 2, 435-441 (1996).
6. S. P. Atamas, V. V. Yurovsky, R. Wise, et al., *Arthritis Rheum.*, **43**, No. 1, 236-238 (2000).
7. P. Chomczynski and N. Sacchi, *Anal. Biochem.*, **162**, No. 1, 156-159 (1987).
8. I. Gautherot, N. Burdin, D. Seguin, et al., *Immunogenetics*, **54**, 635-644 (2002).
9. E. M. Glare, M. Divjak, et al., *J. Allergy Clin. Immunol.*, **104**, 978-982 (1999).
10. S. C. Klein, J. G. Golverdingen, D. F. Van Wichen, et al., *Cell. Immunol.*, **167**, 259-268 (1996).
11. H. D. Perkins, B. H. van Leeuwen, C. M. Hardy, et al., *Cytokine*, **12**, No. 6, 555-565 (2000).
12. L. I. Sakkas, C. Tourtellotte, S. Berney, et al., *Clin. Diagn. Lab. Immunol.*, **6**, No. 5, 660-664 (1999).
13. G. T. Seah, P. S. Gao, J. M. Hopkin, et al., *Am. J. Respir. Crit. Care Med.*, **164**, 1016-1018 (2001).
14. G. T. Seah, G. M. Scott, and G. A. Rook, *J. Infect. Dis.*, **181**, 385-389 (2000).